Overall, the evidence indicates that XRN2 can selectively exert its functions to promote cancer progression and enhance malignant phenotypes by either promoting the maturation of oncogenic miRNAs or degrading tumor-suppressive miRNAs in cancer. The gene discussed is XRN2; the disease is cancer.